Skip to main content
OpenTrials
Completed

NCT Number: NCT01374126

Azithromycin Combination Therapy for the Treatment of Severe Malaria

A randomized controlled trial to assess the safety and efficacy of azithromycin combination therapy for use in severe malaria. This pilot trial will be conducted in uncomplicated malaria patients in southeastern Bangladesh.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MARIB

Bāndarban, Bangladesh

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female participants with a diagnosis of acute falciparum malaria meeting all criteria listed below may be included in the study:

  • Acute symptomatic falciparum malaria infection with a parasite density of 100 to 100,000 asexual parasites/uL as determined on the screening smear with fever (defined as ≥37.5ºC), or reported history of fever within the last 48 hours.
  • Age: 8-65 years old
  • Males or females. All females over the age of 12 are required to have a negative human chorionic gonadotropin (hCG) pregnancy test (urine). All females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception, such as implant, injectable, oral contraceptive(s) with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study
  • Written informed consent obtained
  • Willing to stay under close medical supervision for the study duration
  • Otherwise healthy outpatients

Exclusion criteria

Participants presenting with any of the following will not be included in the study:

  • Pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception (as described in Inclusion Criteria, #3)
  • Mixed malaria infection on admission by malaria smear
  • A previous history of intolerance or hypersensitivity to the study drugs artesunate, azithromycin or to drugs with similar chemical structures
  • Malaria drug therapy administered in the past 30 days by history
  • History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk.
  • Symptoms of severe vomiting (no food or inability to take food during the previous 8 hours).
  • Signs or symptoms of severe malaria (as defined by WHO 2003)
  • Unable and/or unlikely to comprehend and/or follow the protocol

Treatment and study plan

Artesunate

Drug

Artesunate alone

Azithromycin + Artesunate

Drug

Combination of azithromycin + artesunate

Primary outcomes

  1. Safety and Tolerability (Number of Participants with Adverse Events)

    Time frame: 42 days

  2. Adequate Clinical and Parasitological Response (ACPR) on Days 28 and 42

    Time frame: 42 days

Sponsors and collaborators

Lead sponsor

Medical University of Vienna

Other

Collaborators

  • International Centre for Diarrhoeal Disease Research, Bangladesh

Registry information

Official study title

Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jun 15, 2011
Registry last updated
Aug 23, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.